PAMAM-Calix-Dendrimers: Second Generation Synthesis, Fluorescent Properties and Catecholamines Binding

A convenient method for the synthesis of the second generation of PAMAM dendrimers based on a <i>p-tert</i>-butylthiacalix[4]arene core in <i>cone</i>, <i>partial cone</i> and <i>1,3-alternate</i> conformations was developed. Unusual fluorescence of th...

Full description

Saved in:
Bibliographic Details
Main Authors: Olga Mostovaya (Author), Igor Shiabiev (Author), Dmitry Pysin (Author), Alesia Stanavaya (Author), Viktar Abashkin (Author), Dzmitry Shcharbin (Author), Pavel Padnya (Author), Ivan Stoikov (Author)
Format: Book
Published: MDPI AG, 2022-12-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A convenient method for the synthesis of the second generation of PAMAM dendrimers based on a <i>p-tert</i>-butylthiacalix[4]arene core in <i>cone</i>, <i>partial cone</i> and <i>1,3-alternate</i> conformations was developed. Unusual fluorescence of the obtained PAMAM-calix-dendrimers has been found and explained. The binding ability of the synthesized dendrimers toward catecholamines (dopamine, <i>L</i>-adrenaline and <i>L</i>-noradrenaline) was shown by UV-Vis, fluorescence, 1D and 2D NMR spectroscopy and the binding constants (logK<sub>a</sub> 3.85-4.74) calculated. As was shown, the PAMAM-calix-dendrimers bind catecholamines by the internal cavities. All the studied hormones were most efficiently bound by the dendrimers bearing a macrocyclic core in <i>1,3-alternate</i> conformation. The size of the formed supramolecular systems of dendrimer/catecholamine was established by the DLS method. A decrease in hemolytic activity of the PAMAM-calix-dendrimers with an increase in the generation number of a dendrimer was shown for the dendrimers with a core in <i>1,3-alternate</i> conformation. The prospects for the use of the synthesized dendrimers with the macrocyclic core as drug delivery agents were discussed.
Item Description:10.3390/pharmaceutics14122748
1999-4923